In This Article:
NEW YORK, NY / ACCESSWIRE / May 5, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Spectrum Brands Legacy, Inc. (f/k/a Spectrum Brands Holdings, Inc.) (SPB)
Class Period: June 14, 2016 - November 16, 2018
Lead Plaintiff Deadline : May 6, 2019
Join the action: https://www.zlk.com/pslra-1/spectrum-brands-holdings-inc-loss-form?prid=1394&wire=1
Allegations: Spectrum Brands Legacy, Inc. (f/k/a Spectrum Brands Holdings, Inc.) made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Spectrum had been self-inflicting the operational issues at its Ohio and Kansas facilities; (ii) these operational issues were, in fact, recurring in nature; (iii) these operational issues would continuously impact production, shipping levels and sales; and (iv) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.
To learn more about the Spectrum Brands Legacy, Inc. (f/k/a Spectrum Brands Holdings, Inc.) class action contact jlevi@levikorsinsky.com.
Indivior PLC (INVVY)
Class Period: March 10, 2015 - April 9, 2019
Lead Plaintiff Deadline : June 24, 2019
Join the action: https://www.zlk.com/pslra-1/indivior-plc-loss-form?prid=1394&wire=1
Allegations: Indivior PLC made materially false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Indivior PLC class action contact jlevi@levikorsinsky.com.
Boston Scientific Corporation (BSX)
Class Period: February 26, 2015 - April 16, 2019
Lead Plaintiff Deadline : June 24, 2019
Join the action: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-form?prid=1394&wire=1
Allegations: During the class period, Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific's surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific's continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.